Hertility Health Raises £4.2M in Seed Funding

From left to right: Dr. Natalie Getreu – COO and Co-Founder, Dr. Helen O’Neill – CEO and Founder and Deirdre O’Neill – CCO and Co-Founder

Hertility Health, a UK-based new women’s health startup, closed a £4.2m seed funding round.

The round was led by LocalGlobe, Venrex, and some key angel investors including former CEO of Bupa, Evelyn Bourke, CEO of Nested and the unicorn company GoCardless, Matt Robinson.

The company intends to use the funds to:

  • expand its current product offering of fertility and hormone testing, menopause, miscarriage, postnatal care, polycyctic ovarian syndrome (PCOS) and endometriosis testing,
  • aid the expansion of its current clinical trials which aim to reduce the diagnosis time for some of the most common reproductive conditions, and
  • establish it as a scientific and clinical educational health hub for women.  

Led by Dr. Natalie Getreu – COO, Dr. Helen O’Neill – CEO, and Deirdre O’Neill – CCO, Hertility Health is a science-driven network of care created to give reproductive and hormone health the attention it needs. The company offers not just a test, but a triage system, and their services connect women with licensed experts and clinics, providing them with a personalised care pathway. Results are then published onto a personalised online dashboard, offering insights into ovarian reserve, menstrual cycle and ovulation, hormone health and highlights any fertility red flags. 

Hertility Health has already served over 2,000 women to understand their reproductive health and infertility risks, working with world experts to provide personalised care pathways that help with all aspects of women’s health, including  symptom management, egg freezing and IVF.